Highest-materiality recent filing
MiNK Q2 2026 net loss $3.1M, cash $8.8M; Phase 2 ALI data positive
Net loss $3.1M ($0.62/share) vs $4.2M ($1.06) in Q2 2025; six-month loss $5.9M vs $7.0M.
Quorum of 3,277,906 shares (65.79% of outstanding) present at annual meeting.
MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS
Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.
MiNK Therapeutics reports FY2025 net loss $12.5M; ARDS Phase 2 trial initiation in 1H 2026
Net loss FY2025 $12.5M ($2.93/sh) vs $10.8M ($2.86/sh) in FY2024; cash $13.4M at year end, plus $3.0M raised since.
MiNK Therapeutics confirms active discussions for combination trials and strategic investments
Company is in active discussions with multiple parties for potential combination trials of agenT-797.
MiNK Therapeutics appoints new Principal Financial Officer and Principal Accounting Officer
Melissa Orilall, VP Global Financial Operations at Agenus, appointed Principal Financial Officer effective March 13, 2026.
Director Robert Kadlec resigns from MiNK Therapeutics board for U.S. government role
Robert Kadlec, MD, resigned from the Board of Directors effective December 29, 2025.
MiNK Therapeutics Q3 net loss $2.9M; durable remissions with agenT-797, cash runway through 2026
Net loss $2.9M ($0.65/share) in Q3 2025 vs $1.8M ($0.46) in Q3 2024.
MiNK Therapeutics appoints trauma expert Col. (Ret.) John Holcomb to Board
Dr. John Holcomb elected as Class II director; term expires at 2026 annual meeting.
MiNK Therapeutics Q2 2025 net loss $4.2M; extends runway with $13M raise; GvHD grants awarded
Cash at Q2 end $1.6M; raised $13M post-quarter; runway extended beyond mid-2026.
MiNK Therapeutics enters $50M ATM equity offering agreement with B. Riley Securities
Maximum aggregate offering price of $50M in common stock to be sold at market prices.
Complete and durable remission in metastatic testicular cancer patient after single infusion of agenT-797 plus nivolumab, per Nature's Oncogene publication.
Jennifer Buell and Ulf Wiinberg elected as Class I directors with 2,337,073 and 2,312,077 votes For, respectively.
MiNK Therapeutics reports Q1 net loss of $2.8M; cash burn down; clinical progress in iNKT platform
Net loss of $2.8M ($0.70/sh) vs $3.8M ($1.10/sh) YoY; cash used in ops down to $1.3M from $2.5M.
MiNK Therapeutics reports FY2024 net loss of $10.8M, improved from $22.5M in 2023
Net loss for FY2024 was $10.8M ($2.86/diluted share) vs $22.5M ($6.54/share) in 2023.
MiNK Therapeutics stockholders approve 1-for-10 reverse stock split effective Jan 28
Special meeting held Jan 17, 2025; 27,582,512 shares voted (quorum).
MiNK Therapeutics Q3 2024 net loss narrows to $1.8M; cash at $6.3M
Net loss of $1.8M ($0.05 per share) improved from $5.1M ($0.15) in Q3 2023.
MiNK appoints former HHS ASPR Robert Kadlec to board
Dr. Robert Kadlec elected Class II director effective Oct. 30, 2024; term expires at 2026 annual meeting.
MiNK Therapeutics CSO Marc Van Dijk transitions to advisory roles effective Nov 15
Dr. Marc Van Dijk leaves Chief Scientific Officer role, becomes Scientific Advisory Board Member and Strategic Consultant.
MiNK Therapeutics receives Nasdaq MVLS deficiency notice; has until March 12, 2025 to comply
Received Nasdaq letter on September 13, 2024 for failing MVLS (minimum value of listed securities) requirement.
MiNK Therapeutics receives Nasdaq delisting notice for failing to meet $1.00 bid price rule
Nasdaq notified MiNK on Aug 27, 2024 that it failed to regain compliance with the $1.00 minimum bid price within the 180-day grace period ending Aug 26, 2024.
MiNK Q2 net loss narrows to $2.7M; cash $9.3M; clinical programs advance
Net loss Q2 2024 $2.7M ($0.07/sh) vs $6.2M ($0.18/sh) Q2 2023; 6-month loss $6.5M vs $11.9M.
MiNK Therapeutics stockholders elect directors, ratify KPMG at 2024 annual meeting
Annual meeting held June 12, 2024; 28,359,271 shares (81.71%) present or represented.
MiNK Therapeutics raises ~$5.8M via 4.64M shares at $1.25/share, 25% premium to VWAP
Issued 4,640,000 common shares at $1.25 per share, a 25% premium to 30-day VWAP.
MiNK Q1 net loss narrows to $3.8M; $5.8M PIPE to fund MiNK-215 IND in 2025
Net loss of $3.8M ($0.11 per share) vs $5.7M ($0.17) YoY; cash used in ops $2.5M.
MiNK Therapeutics reports FY2023 net loss $22.5M; cash $3.4M at year-end
Net loss for 2023 was $22.5M ($0.65/share) vs. $28.0M ($0.83/share) in 2022.
MiNK receives Nasdaq deficiency notices for MVLS and minimum bid price; faces potential delisting
On Feb 23, 2024, Nasdaq notified MiNK that its MVLS was below $35M for 30 consecutive days; compliance deadline Aug 21, 2024.
MiNK Therapeutics issues up to $5.0M convertible promissory note to Agenus at 2% interest
Principal amount up to $5.0M; interest rate 2% per annum, accruing but payable upon conversion or maturity.
MiNK Therapeutics Q3 net loss $5.1M; cash $6.4M; agenT-797 shows durable solid tumor benefit
Cash $6.4M at Sep 30, 2023, down from $19.6M at Dec 31, 2022; Q3 cash used in ops $4.2M.
MiNK Therapeutics director Dr. John Baldoni resigns effective Oct 31, 2023
Dr. John Baldoni resigns from board effective Oct 31, 2023, citing manufacturing advancements reducing need for his technical contributions.
MiNK reports Q2 2023 net loss $6.2M; cash low at $10.6M; Phase 2 gastric trial planned
Six-month 2023 net loss $11.9M ($0.35/share) vs $13.9M ($0.41) in prior year period.
Garo Armen received 29,157,446 for and 282,326 withheld; Barbara Ryan 29,193,530 for and 246,242 withheld.
MiNK Therapeutics Q1 net loss $5.7M; agenT-797 shows durable responses in solid tumors
Net loss $5.7M ($0.17/share) vs $7.8M ($0.23) in Q1 2022; cash $14.9M at March 31, 2023.
MiNK Therapeutics reports Q4 net loss $7.8M; cash $19.6M at Dec 31, 2022
Net loss for Q4 2022: $7.8M ($0.23/share) vs $5.8M ($0.18) in Q4 2021.
MiNK Therapeutics Q3 2022 net loss $6.3M, cash $24.2M; pipeline and R&D day updates
Net loss $6.3M ($0.19/share) in Q3 2022 vs $14.3M ($0.59/share) in Q3 2021; nine-month loss $20.2M.
MiNK Q2 net loss $6.1M; cash $29.8M; DARPA selects AgenT-797; clinical data updates expected 2H22
Cash $29.8M as of June 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $4.6M for Q2.
MiNK Therapeutics enters amended intercompany services agreement with Agenus effective April 1, 2022
New agreement covers G&A, R&D, and shared services; MiNK pays 10% of Agenus' G&A costs.
MiNK adopts Executive Change of Control Plan; stockholders elect directors, ratify KPMG
Board approved Executive Change of Control Plan providing 50% time-based equity vesting upon a change of control.
MiNK Q1 2022 net loss $7.8M ($0.23/share); cash $34.7M; clinical milestones on track
Net loss $7.8M vs $3.8M YoY; per share loss $0.23 vs $0.16; non-cash expenses $813K.
MiNK Therapeutics finalizes employment agreements for CEO ($425k) and CSO (£260k)
CEO Dr. Buell: $425,000 base salary, 50% bonus target, compensation retroactive to Jan 1, 2022.
MiNK Therapeutics board member Dr. Walter Flamenbaum retires as planned
Dr. Walter Flamenbaum retired from the Board of Directors effective December 31, 2021.
MiNK Therapeutics files amended charter post-IPO, authorizing 150M common and 5M preferred shares
Amended charter and bylaws became effective upon IPO closing on October 19, 2021.
On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., ("MiNK") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.
Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.
On October 12, 2023, Dr. John Baldoni sent notice of his resignation as a director at MiNK Therapeutics, Inc. (the "Company"), effective October 31, 2023.
Dr. Walter Flamenbaum retired from the Board of Directors of MiNK Therapeutics, Inc. (the “Company”), effective December 31, 2021.
Max materiality 0.85 · Median 0.60 · Most common event earnings